N-Acylhydrazones as inhibitors of PDE10A

Gage, Jennifer L.; Onrust, René; Johnston, Derek; Osnowski, Andrew P.; Macdonald, Wendy; Mitchell, Lee; Ürögdi, László; Rohde, Alex; Harbol, Kevin; Gragerov, Sasha; Dormán, György; Wheeler, T. S.; Florio, Vince; Cutshall, Neil S.

doi:10.1016/j.bmcl.2011.05.100

Cited by 32 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first hybridized series was reported by Omeros corporation [26]. The first hybridized series was reported by Omeros corporation [26].…”

Section: Pf-2545920/papaverine/quinazoline Hybrid Series Of Inhibitorsmentioning

confidence: 99%

The Function, Enzyme Kinetics, Structural Biology, and Medicinal Chemistry of PDE10A

Chappie

2014

Phosphodiesterases and Their Inhibitors

View full text Add to dashboard Cite

Since phosphodiesterase 10A (PDE10A) was first cloned and characterized in 1999 [1], significant investigation into the biological relevance of the protein and identification of enzyme inhibitors has been conducted. Understanding of the enzyme localization has led to the pursuit of PDE10 inhibitors as a potential target for treating central nervous system (CNS) disorders [2]. PDE10A is primarily expressed in the medium spiny neurons of the striatum, leading to significant investigation as to whether PDE10A has a potential role in treating movement disorders. PDE10A affects the same pool of cyclic adenosine monophosphate (cAMP) that dopamine (D2) neurons modulate, and thus schizophrenia research has been at the forefront [3]. Numerous reports have highlighted that PDE10A inhibitors are active in preclinical models where the marketed antipsychotics show efficacy. These include reductions in locomotor activity and conditioned avoidance responding. More recently, research has also disclosed that PDE10A inhibitors may have therapeutic potential in the treatment of Huntington's disease with activity in transgenic mouse models [4].Aside from the heavily studied CNS function of PDE10A, there are a few new reports of PDE10A localization and function outside the basal ganglia. One report finds the PDE10A protein expression in rat retina to be equivalent to the amount of expression of PDE10A in the striatum [5]. PDE10A protein expression is also abundant in photoreceptors and neurons in the inner nuclear layer of the retina. Evidence for the role of PDE10A in managing daily circadian rhythms is supported by the change in mRNA and protein levels in response to changes in the light cycle. Another report finds that PDE10A is a critical regulator of cAMP and cAMP response element-binding protein (CREB) in pulmonary arterial smooth muscle cells [6]. Rats with monocrotaline-induced pulmonary hypertension were dosed for 35 days with papaverine, and this resulted in 40-50% reduction in the hemodynamic effects of pulmonary hypertension and pulmonary vascular remodeling.

show abstract

“…The first hybridized series was reported by Omeros corporation [26]. The first hybridized series was reported by Omeros corporation [26].…”

Section: Pf-2545920/papaverine/quinazoline Hybrid Series Of Inhibitorsmentioning

confidence: 99%

The Function, Enzyme Kinetics, Structural Biology, and Medicinal Chemistry of PDE10A

Chappie

2014

Phosphodiesterases and Their Inhibitors

View full text Add to dashboard Cite

show abstract

“…The first one claims sulfanyl acetic acid hydrazides like compound 20 (6-methoxy-2-methyl-quinolin-4-ylsulfanyl)-acetic acid [1-(3,4,5-trimethoxy-phenyl)-meth-(E)-ylidene]-hydrazide [35], whereas the second claims substituted alkoxybenzylidene derivatives as PDE10 inhibitors like compound 21 [36]. The discovery, SAR studies and optimization studies are the subjects of two recent publications [37,38]. In a later application, compounds where the hydrazide structural motif have been replaced by substituted heterocyclic phenylfuranyl-heteroaryl-phenyl-ethanone derivatives and analogs are claimed as PDE10 inhibitors, exemplified by compound 22, which was shown to significantly reduce the number of avoidance responses in the CAR model at 10 mg/kg (p.o.)…”

Section: Omeros Corpmentioning

confidence: 99%

Phosphodiesterase 10A inhibitors: a 2009 – 2012 patent update

Kehler

2012

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

show abstract

“…Hydrazones [131] have inhibited PDE10A-a phosphodiesterase responsible for neurological and psychological disorder such as Parkinson's, Schizophrenia and Huntington's disease (Gage et al, 2011). The anticonvulsant potential of some hydrazone derivatives [91], [92] having long duration of action and a rapid onset of action (Kaushik et al, 2010).…”

Section: Central Nervous Systemmentioning

confidence: 99%

Pharmacologically potentials of hydrazonone containing compounds: a promising scaffold

Asif

2014

International Journal of Advanced Chemistry

View full text Add to dashboard Cite

N-Acylhydrazones as inhibitors of PDE10A

Cited by 32 publications

References 21 publications

The Function, Enzyme Kinetics, Structural Biology, and Medicinal Chemistry of PDE10A

The Function, Enzyme Kinetics, Structural Biology, and Medicinal Chemistry of PDE10A

Phosphodiesterase 10A inhibitors: a 2009 – 2012 patent update

Pharmacologically potentials of hydrazonone containing compounds: a promising scaffold

Contact Info

Product

Resources

About